BNP Paribas Financial Markets lessened its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 83.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,555 shares of the medical equipment provider's stock after selling 147,371 shares during the period. BNP Paribas Financial Markets' holdings in NovoCure were worth $851,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of NVCR. GeoWealth Management LLC acquired a new stake in shares of NovoCure during the 4th quarter worth approximately $27,000. Lindbrook Capital LLC boosted its stake in NovoCure by 189.2% in the fourth quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider's stock valued at $55,000 after acquiring an additional 1,213 shares during the last quarter. Blue Trust Inc. grew its holdings in NovoCure by 70.7% during the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider's stock worth $56,000 after acquiring an additional 781 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of NovoCure during the 4th quarter valued at $70,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of NovoCure by 57.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,321 shares of the medical equipment provider's stock valued at $129,000 after purchasing an additional 1,575 shares during the period. Institutional investors and hedge funds own 84.61% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently commented on NVCR. Wall Street Zen lowered NovoCure from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their price target on NovoCure from $29.00 to $28.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Wedbush reduced their price objective on NovoCure from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 16th. Finally, Piper Sandler cut their target price on NovoCure from $42.00 to $34.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $32.83.
Check Out Our Latest Analysis on NVCR
NovoCure Stock Up 3.5%
Shares of NovoCure stock traded up $0.64 during trading hours on Tuesday, reaching $19.18. 1,352,043 shares of the company's stock were exchanged, compared to its average volume of 1,144,308. The stock has a market cap of $2.14 billion, a P/E ratio of -13.70 and a beta of 0.73. The company has a 50 day moving average of $17.51 and a two-hundred day moving average of $21.87. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27. NovoCure Limited has a fifty-two week low of $14.17 and a fifty-two week high of $34.13.
NovoCure (NASDAQ:NVCR - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The medical equipment provider reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.16. The firm had revenue of $154.99 million during the quarter, compared to analysts' expectations of $147.57 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.36) earnings per share. On average, sell-side analysts forecast that NovoCure Limited will post -1.3 EPS for the current fiscal year.
About NovoCure
(
Free Report)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
See Also
Before you consider NovoCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovoCure wasn't on the list.
While NovoCure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
